BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Xcovery Holdings readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Xcovery Holdings's drugs run\, fr
 om ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07448116-1978@assetmemo.bio
DTSTAMP:20261121T005943Z
DTSTART;VALUE=DATE:20290201
DTEND;VALUE=DATE:20290202
SUMMARY:Ensacove (Ensartinib): Phase 1/2 readout est. (NCT07448116)
DESCRIPTION:Ensacove (Ensartinib)\, phase 1/2.\nStudy: Study of MCLA-129 in
  Combination With Ensartinib in Patients With Advanced Solid Tumors.\nEsti
 mated primary completion: 1 February 2029. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/ensartinib#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT07448116
URL:https://assetmemo.bio/drug/ensartinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
